- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | TransCode Therapeutics, Inc.: TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up | 147 | PR Newswire | Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors
In the 14 efficacy-evaluable patients:
71.4% stable disease... ► Artikel lesen | |
| 16.09. | RedChip Companies, Inc.: Join Today's Live Investor Webinar with TransCode Therapeutics | 346 | ACCESS Newswire | Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the... ► Artikel lesen | |
| 11.09. | CFO-Wechsel bei Transcode Therapeutics: Fitzgerald tritt zurück, Tattory übernimmt interimistisch | - | Investing.com Deutsch | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | TransCode Therapeutics CFO retires | 1 | Seeking Alpha | ||
| 03.09. | RedChip Companies, Inc.: Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer | 323 | ACCESS Newswire | Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the... ► Artikel lesen | |
| 07.08. | RedChip Companies, Inc.: Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 947 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small... ► Artikel lesen | |
| 03.08. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | 268 | PR Newswire | TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA... ► Artikel lesen | |
| 01.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer | 842 | PR Newswire | BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment... ► Artikel lesen | |
| 22.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 07.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 626 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 390 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,60 | -0,46 % | Jetzt geht es ans Tafelsilber: Neue Firma steht - jetzt eskaliert der Streit um BioNTechs wertvollste Assets | © Foto: Sebastian Christoph Gollnow - dpaDie neue Firma ist gegründet, das Team soll wachsen. Doch bevor Arife durchstarten kann, muss eine Frage geklärt werden, die für BioNTech richtig teuer werden... ► Artikel lesen | |
| QIAGEN | 38,950 | +0,59 % | DAX-Gewinner im September: Die fünf Top-Aktien im DAX - Diese 5 Aktien ließen die Konkurrenz hinter sich | © Foto: Rafael Henrique - picture allianceDer September bringt Bewegung in den DAX. Auf 30-Tage-Sicht konnten vor allem Qiagen, MTU Aero Engines und die Commerzbank überzeugen. Ein Überblick über die... ► Artikel lesen | |
| VALNEVA | 2,643 | -2,29 % | BRANDMELDUNG bei Valneva: Diese brandneue Prognose ändert einfach alles - Dringend handeln! | ||
| NOVAVAX | 9,590 | +0,52 % | Novavax Inc mit PAUKENSCHLAG: Droht die Aktie jetzt der nächste Absturz? - Jetzt unbedingt lesen! | ||
| PALATIN TECHNOLOGIES | 9,050 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| BRAIN BIOTECH | 2,850 | 0,00 % | Brain Biotech erhält 11,5 Millionen Euro - hoher Buchungseffekt belastet | Brain Biotech erhält von Royalty Pharma eine Meilensteinzahlung von 11,51 Millionen Euro. Auslöser ist ein Entwicklungsfortschritt beim Pharmawirkstoff Deucrictibant auf Basis der 2024 geschlossenen... ► Artikel lesen | |
| VIVOSIM LABS | 0,211 | 0,00 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| OCUGEN | 0,939 | +2,74 % | Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa | Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP)... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | +11,05 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,640 | +2,73 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,085 | -1,36 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,340 | +1,62 % | Jefferies bestätigt Kaufempfehlung für Sarepta Therapeutics wegen Pipeline-Potenzial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,955 | -6,41 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,480 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results | Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.